ATROPINE CITRATE

First marketed in 1921

Details

Stereochemistry	RACEMIC
Molecular Formula	C17H23NO3.C6H8O7
Molecular Weight	481.4929
Optical Activity	( + / - )
Defined Stereocenters	3 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)CC(O)(CC(O)=O)C(O)=O.CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C3=CC=CC=C3

InChI

InChIKey=PVFKXEKWGWYDSO-RIMUKSHESA-N

InChI=1S/C17H23NO3.C6H8O7/c1-18-13-7-8-14(18)10-15(9-13)21-17(20)16(11-19)12-5-3-2-4-6-12;7-3(8)1-6(13,5(11)12)2-4(9)10/h2-6,13-16,19H,7-11H2,1H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/t13-,14+,15+,16?;

HIDE SMILES / InChI

Molecular Formula	C17H23NO3
Molecular Weight	289.3694
Charge	0
Count

Stereochemistry	EPIMERIC
Additional Stereochemistry	No
Defined Stereocenters	3 / 4
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	C6H8O7
Molecular Weight	192.1235
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021146s015lbl.pdf
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/mesh/68001285 | http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206289s000lbl.pdf

Atropine inhibits the muscarinic actions of acetylcholine on structures innervated by postganglionic cholinergic nerves, and on smooth muscles which respond to endogenous acetylcholine but are not so innervated. As with other antimuscarinic agents, the major action of atropine is a competitive or surmountable antagonism which can be overcome by increasing the concentration of acetylcholine at receptor sites of the effector organ (e.g., by using anticholinesterase agents which inhibit the enzymatic destruction of acetylcholine). The receptors antagonized by atropine are the peripheral structures that are stimulated or inhibited by muscarine (i.e., exocrine glands and smooth and cardiac muscle). Responses to postganglionic cholinergic nerve stimulation also may be inhibited by atropine but this occurs less readily than with responses to injected (exogenous) choline esters. Atropine is relatively selective for muscarinic receptors. Its potency at nicotinic receptors is much lower, and actions at non-muscarinic receptors are generally undetectable clinically. Atropine does not distinguish among the M1, M2, and M3 subgroups of muscarinic receptors.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Muscarinic acetylcholine receptor M1 168 Target ID: CHEMBL216 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206289s000lbl.pdf	Antagonist 2849	9.34 null [pKi]
Muscarinic acetylcholine receptor M2 121 Target ID: CHEMBL211 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206289s000lbl.pdf	Antagonist 2849	8.95 null [pKi]
Muscarinic acetylcholine receptor M3 160 Target ID: CHEMBL245 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206289s000lbl.pdf	Antagonist 2849	9.15 null [pKi]

Conditions

Condition	Modality	Highest Phase	Product
Bradyasystolic cardiac arrest 8 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021146s015lbl.pdf	Primary	Approved 8583	Atropine sulfate Approved Use Atropine sulfate is indicated for temporary blockade of severe or life threatening muscarinic effects, e.g., as an antisialagogue, an antivagal agent, an antidote for organophosphorus or muscarinic mushroom poisoning, and to treat bradyasystolic cardiac arrest. Launch Date 2001
Organophosphorus poisoning 8 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021146s015lbl.pdf	Primary	Approved 8583	Atropine sulfate Approved Use Atropine sulfate is indicated for temporary blockade of severe or life threatening muscarinic effects, e.g., as an antisialagogue, an antivagal agent, an antidote for organophosphorus or muscarinic mushroom poisoning, and to treat bradyasystolic cardiac arrest. Launch Date 2001
Increased salivary flow 8 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021146s015lbl.pdf	Primary	Approved 8583	Atropine sulfate Approved Use Atropine sulfate is indicated for temporary blockade of severe or life threatening muscarinic effects, e.g., as an antisialagogue, an antivagal agent, an antidote for organophosphorus or muscarinic mushroom poisoning, and to treat bradyasystolic cardiac arrest. Launch Date 2001
Vagus nerve activation 8 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021146s015lbl.pdf	Primary	Approved 8583	Atropine sulfate Approved Use Atropine sulfate is indicated for temporary blockade of severe or life threatening muscarinic effects, e.g., as an antisialagogue, an antivagal agent, an antidote for organophosphorus or muscarinic mushroom poisoning, and to treat bradyasystolic cardiac arrest. Launch Date 2001
Muscarinic mushroom poisoning 8 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021146s015lbl.pdf	Primary	Approved 8583	Atropine sulfate Approved Use Atropine sulfate is indicated for temporary blockade of severe or life threatening muscarinic effects, e.g., as an antisialagogue, an antivagal agent, an antidote for organophosphorus or muscarinic mushroom poisoning, and to treat bradyasystolic cardiac arrest. Launch Date 2001

C_max

Value	Dose	Analyte	Population
9.6 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/212319s000lbl.pdf	1.67 mg single, intramuscular dose: 1.67 mg route of administration: Intramuscular experiment type: SINGLE co-administered:	ATROPINE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN
860 pg/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/3046815	0.4 mg single, ocular dose: 0.4 mg route of administration: Ocular experiment type: SINGLE co-administered:	ATROPINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
11.7 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/3740650	1.67 mg single, intramuscular dose: 1.67 mg route of administration: Intramuscular experiment type: SINGLE co-administered:	ATROPINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
43245 pg × min/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/3046815	0.4 mg single, ocular dose: 0.4 mg route of administration: Ocular experiment type: SINGLE co-administered:		ATROPINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
47.6 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/3740650	1.67 mg single, intramuscular dose: 1.67 mg route of administration: Intramuscular experiment type: SINGLE co-administered:		ATROPINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
4.1 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/3740650	1.67 mg single, intramuscular dose: 1.67 mg route of administration: Intramuscular experiment type: SINGLE co-administered:		ATROPINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
82% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/212319s000lbl.pdf	1.67 mg single, intramuscular dose: 1.67 mg route of administration: Intramuscular experiment type: SINGLE co-administered:		ATROPINE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
0.1 mg/kg single, intravenous Dose: 0.1 mg/kg Route: intravenous Route: single Dose: 0.1 mg/kg Sources: https://pubmed.ncbi.nlm.nih.gov/29316984	unhealthy, 10 years Health Status: unhealthy Age Group: 10 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/29316984	Disc. AE: Kounis syndrome, Chest discomfort... AEs leading to discontinuation/dose reduction: Kounis syndrome (1 patient) Chest discomfort (1 patient) Nausea (1 patient) Vomiting (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/29316984
0.5 % 1 times / day multiple, ophthalmic Highest studied dose Dose: 0.5 %, 1 times / day Route: ophthalmic Route: multiple Dose: 0.5 %, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/27101751	unhealthy, 10.3 years (range: 2.7–16.8 years) Health Status: unhealthy Age Group: 10.3 years (range: 2.7–16.8 years) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/27101751	Other AEs: Photophobia, Reading disorder... Other AEs: Photophobia (70%) Reading disorder (25.9%) Headache (21.7%) Hot flushes (3.3%) Conjunctivitis (1.7%) Blepharitis (1.7%) Sources: https://pubmed.ncbi.nlm.nih.gov/27101751
1 mg single, sublingual Overdose Dose: 1 mg Route: sublingual Route: single Dose: 1 mg Sources: https://pubmed.ncbi.nlm.nih.gov/33521988	unhealthy Health Status: unhealthy Sources: https://pubmed.ncbi.nlm.nih.gov/33521988	Other AEs: Adverse event... Other AEs: Adverse event (severe) Sources: https://pubmed.ncbi.nlm.nih.gov/33521988

AEs

AE	Significance	Dose	Population
Chest discomfort	1 patient Disc. AE	0.1 mg/kg single, intravenous Dose: 0.1 mg/kg Route: intravenous Route: single Dose: 0.1 mg/kg Sources: https://pubmed.ncbi.nlm.nih.gov/29316984	unhealthy, 10 years Health Status: unhealthy Age Group: 10 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/29316984
Kounis syndrome	1 patient Disc. AE	0.1 mg/kg single, intravenous Dose: 0.1 mg/kg Route: intravenous Route: single Dose: 0.1 mg/kg Sources: https://pubmed.ncbi.nlm.nih.gov/29316984	unhealthy, 10 years Health Status: unhealthy Age Group: 10 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/29316984
Nausea	1 patient Disc. AE	0.1 mg/kg single, intravenous Dose: 0.1 mg/kg Route: intravenous Route: single Dose: 0.1 mg/kg Sources: https://pubmed.ncbi.nlm.nih.gov/29316984	unhealthy, 10 years Health Status: unhealthy Age Group: 10 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/29316984
Vomiting	1 patient Disc. AE	0.1 mg/kg single, intravenous Dose: 0.1 mg/kg Route: intravenous Route: single Dose: 0.1 mg/kg Sources: https://pubmed.ncbi.nlm.nih.gov/29316984	unhealthy, 10 years Health Status: unhealthy Age Group: 10 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/29316984
Blepharitis	1.7%	0.5 % 1 times / day multiple, ophthalmic Highest studied dose Dose: 0.5 %, 1 times / day Route: ophthalmic Route: multiple Dose: 0.5 %, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/27101751	unhealthy, 10.3 years (range: 2.7–16.8 years) Health Status: unhealthy Age Group: 10.3 years (range: 2.7–16.8 years) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/27101751
Conjunctivitis	1.7%	0.5 % 1 times / day multiple, ophthalmic Highest studied dose Dose: 0.5 %, 1 times / day Route: ophthalmic Route: multiple Dose: 0.5 %, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/27101751	unhealthy, 10.3 years (range: 2.7–16.8 years) Health Status: unhealthy Age Group: 10.3 years (range: 2.7–16.8 years) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/27101751
Headache	21.7%	0.5 % 1 times / day multiple, ophthalmic Highest studied dose Dose: 0.5 %, 1 times / day Route: ophthalmic Route: multiple Dose: 0.5 %, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/27101751	unhealthy, 10.3 years (range: 2.7–16.8 years) Health Status: unhealthy Age Group: 10.3 years (range: 2.7–16.8 years) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/27101751
Reading disorder	25.9%	0.5 % 1 times / day multiple, ophthalmic Highest studied dose Dose: 0.5 %, 1 times / day Route: ophthalmic Route: multiple Dose: 0.5 %, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/27101751	unhealthy, 10.3 years (range: 2.7–16.8 years) Health Status: unhealthy Age Group: 10.3 years (range: 2.7–16.8 years) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/27101751
Hot flushes	3.3%	0.5 % 1 times / day multiple, ophthalmic Highest studied dose Dose: 0.5 %, 1 times / day Route: ophthalmic Route: multiple Dose: 0.5 %, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/27101751	unhealthy, 10.3 years (range: 2.7–16.8 years) Health Status: unhealthy Age Group: 10.3 years (range: 2.7–16.8 years) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/27101751
Photophobia	70%	0.5 % 1 times / day multiple, ophthalmic Highest studied dose Dose: 0.5 %, 1 times / day Route: ophthalmic Route: multiple Dose: 0.5 %, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/27101751	unhealthy, 10.3 years (range: 2.7–16.8 years) Health Status: unhealthy Age Group: 10.3 years (range: 2.7–16.8 years) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/27101751
Adverse event	severe	1 mg single, sublingual Overdose Dose: 1 mg Route: sublingual Route: single Dose: 1 mg Sources: https://pubmed.ncbi.nlm.nih.gov/33521988	unhealthy Health Status: unhealthy Sources: https://pubmed.ncbi.nlm.nih.gov/33521988

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
OCT1 620 OCT2 779 OCT3 159

Drug as perpetrator

Target	Modality	Activity
OCT1 656	inhibitor 4027 Sources: http://www.ncbi.nlm.nih.gov/pubmed/16263091	yes [IC50 1.2 uM]
OCT2 782	inhibitor 4027 Sources: http://www.ncbi.nlm.nih.gov/pubmed/16263091	yes [IC50 39 uM]
OCT3 161	inhibitor 4027 Sources: http://www.ncbi.nlm.nih.gov/pubmed/16263091	yes [IC50 466 uM]

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:16684	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:16684
ChemicalBook	CB2163178	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB2163178
eMolecules	478873	https://www.emolecules.com/cgi-bin/more?vid=478873
MolPort	MolPort-001-742-593	https://www.molport.com/shop/molecule-link/MolPort-001-742-593

PubMed

Title	Date	PubMed
Endothelin receptors in human and guinea-pig gallbladder muscle.	2001-04-20	11231044
Localisation and neural control of the release of calcitonin gene-related peptide (CGRP) from the isolated perfused porcine ileum.	2001-04-20	11231043
Orally administered atropine enhances motor cortex excitability: a transcranial magnetic stimulation study in human subjects.	2001-03-16	11226633
Neural-epithelial cell interplay: in vitro evidence that vagal mediators increase PGE2 production by human nasal epithelial cells.	2001-03-03	11227912
5-Hydroxytryptamine and atropine inhibit nicotinic receptors in submucosal neurons.	2001-03-02	11239911
Activation of the parasympathetic nervous system is necessary for normal meal-induced insulin secretion in rhesus macaques.	2001-03	11238517
From 'captive' agonism to insurmountable antagonism: demonstrating the power of analytical pharmacology.	2001-03	11236130
Pharmacological characterization of locomotor sensitization induced by chronic phencyclidine administration.	2001-03	11181923
Low-affinity M(2) receptor binding state mediates mouse atrial bradycardia: comparative effects of carbamylcholine and the M(1) receptor agonists sabcomeline and xanomeline.	2001-03	11181912
Respective roles of carbamylcholine and cyclic adenosine monophosphate in their synergistic regulation of cell cycle in thyroid primary cultures.	2001-03	11181542
Role of a central muscarinic cholinergic pathway for relaxation of the proximal urethra during the voiding phase in rats.	2001-03	11176529
Initiation of distension-induced descending peristaltic reflex in opossum esophagus: role of muscle contractility.	2001-03	11171625
Muscarinic stimulation increases basal Ca(2+) and inhibits spontaneous Ca(2+) transients in murine colonic myocytes.	2001-03	11171588
Photochemical N-demethylation of alkaloids.	2001-02-26	11229743
Facilitation of transmitter release in the urinary bladders of neonatal and adult rats via alpha1-adrenoceptors.	2001-02-23	11230992
Binding of nicotinic ligands to and nicotine-induced calcium signaling in Trypanosoma cruzi.	2001-02-23	11181045
Sympathetic control of nasal blood flow in the rat mediated by alpha(1)-adrenoceptors.	2001-02-16	11226401
Characterisation of the prejunctional inhibitory muscarinic receptor on cholinergic nerves in the rat urinary bladder.	2001-02-16	11226391
[Availability of antidotes in French emergency medical aid units].	2001-02-03	11229303
Mechanisms of hydrogen peroxide-induced relaxation in rabbit mesenteric small artery.	2001-02-02	11166293
Muscarinic receptor subtypes and calcium signaling in Fischer rat thyroid cells.	2001-02-01	11172738
Acetylcholine-evoked calcium increases in Deiters' cells of the guinea pig cochlea suggest alpha9-like receptors.	2001-02-01	11170174
Differences in electromechanical coupling between bradykinin and the nonpeptide kinin B2 receptor agonist, FR 190997, in the circular muscle of guinea-pig colon.	2001-02	11218070
Accelerated dobutamine stress testing: safety and feasibility in patients with known or suspected coronary artery disease.	2001-02	11214744
On the mechanisms of cholinergic control of the sinoatrial node discharge.	2001-02	11210000
Pharmacological characterization of muscarinic receptors in dog isolated ciliary and urinary bladder smooth muscle.	2001-02	11181424
Antispasmodic activity of the fruits of Helicteres isora Linn.	2001-02	11180523
Sublingual hyoscyamine sulfate in combination with ketorolac tromethamine for ureteral colic: a randomized, double-blind, controlled trial.	2001-02	11174230
Reversal of rocuronium with edrophonium during propofol versus sevoflurane anesthesia.	2001-02	11167172
Role of preoptic and anterior hypothalamic cholinergic input on water intake and body temperature.	2001-01-19	11166703
[Atropine. Principles and rules of utilization].	2001-01-15	11234098
Determination of scopolamine in human serum and microdialysis samples by liquid chromatography-tandem mass spectrometry.	2001-01-05	11204211
Role of PAG in the antinociception evoked from the medial or central amygdala in rats.	2001-01-01	11226714
[Experiences with cycloplegic drops in German-speaking centers of pediatric ophthalmology and stabology--results of a 1999 survey].	2001-01	11225396
Preanaesthetic use of atropine in small animals.	2001-01	11221564
On the interactions between antimuscarinic atropine and NMDA receptor antagonists in anticholinesterase-treated mice.	2001-01	11218047
Mechanisms of acetylcholine-induced vasorelaxation in high K+-stimulated rabbit renal arteries.	2001-01	11217061
Increase of peak expiratory flow by atropine is dependent on circadian rhythm.	2001-01	11212055
High concentration sevoflurane induction of anesthesia accelerates onset of vecuronium neuromuscular blockade.	2001-01	11212046
[Marked bradycardia during anesthetic induction treated with temporary cardiac pacing in a patient with latent sick sinus syndrome].	2001-01	11211756
Tachykinins contribute to nerve-mediated contractions in the human esophagus.	2001-01	11208712
Influence of patient posture on oxygen saturation during fibre-optic bronchoscopy.	2001-01	11207018
A clinico-epidemiological study of organophosphorus poisoning at a rural-based teaching hospital in eastern Nepal.	2001-01	11205599
Tris(2,2'-bipyridine)ruthenium(II) electrogenerated chemiluminescence of alkaloid type drugs with solid phase extraction sample preparation.	2001-01	11205508
Muscarinic activation of transient inward current and contraction in canine colon circular smooth muscle cells.	2001-01	11201499
Hypotensive infarction of the spinal cord in a rhesus macaque (Macaca mulatta).	2001-01	11199156
Spectral analysis of circadian rhythms in heart rate variability of dogs.	2001-01	11197557
Effects of VIP and NO on the motor activity of vascularly perfused rat proximal colon.	2001-01	11179602
Unplanned administration of atropine, succinylcholine and lidocaine.	2001-01	11167461
Neuropharmacological actions of some binuclear lanthanide(III) complexes.	2001-01	11166680

Patents

Sample Use Guides

In Vivo Use Guide

Atropine as an antisialagogue or for antivagal effects: initial single dose of 0.5 mg to 1 mg; as an antidote for organophosporous or muscarinic mushroom poisoning: initial single dose of 2 mg to 3 mg, repeated every 20-30 minutes; for bradyasystolic cardiac arrest: 1 mg dose, repeated every 3-5 minutes if asystole persists; in patients with coronary artery disease: total dose should not exceed 0.03 mg/kg to 0.04 mg/kg.

Route of Administration: Other

In Vitro Use Guide

Atropine in doses -5.44 to -4.74 log mol/L totally inhibited the contraction induced by acetylcholine and carbachol in segmental pulmonary artery specimens taken from the patients undergoing thoracic surgery.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:08:37 GMT 2025` Edited by `admin` on `Mon Mar 31 18:08:37 GMT 2025`
Record UNII	058DSI3OLC
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ATROPINE CITRATE

Common Name

English

BENZENEACETIC ACID, .ALPHA.-(HYDROXYMETHYL)-8-METHYL-8-AZABICYCLO(3.2.1)OCT-3-YL ESTER ENDO-, 2-HYDROXY-1,2,3-PROPANETRICARBOXYLATE (SALT)

Preferred Name

English

Code System Code Type Description

PUBCHEM

71587492

Created by admin on Mon Mar 31 18:08:37 GMT 2025 , Edited by admin on Mon Mar 31 18:08:37 GMT 2025

PRIMARY

CAS

137414-35-8

Created by admin on Mon Mar 31 18:08:37 GMT 2025 , Edited by admin on Mon Mar 31 18:08:37 GMT 2025

PRIMARY

FDA UNII

058DSI3OLC

Created by admin on Mon Mar 31 18:08:37 GMT 2025 , Edited by admin on Mon Mar 31 18:08:37 GMT 2025

PRIMARY

Related Record Type Details


					XF417D3PSL

Anhydrous citric acid

PARENT -> SALT/SOLVATE

Amount:

Related Record Type Details


					7C0697DR9I

ATROPINE

ACTIVE MOIETY

Amount:

Details

SMILES

InChI

DescriptionSources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021146s015lbl.pdfCurator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/mesh/68001285 | http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206289s000lbl.pdf

CNS Activity

Originator

Approval Year

Targets

Conditions

Approved Use

Launch Date

Approved Use

Launch Date

Approved Use

Launch Date

Approved Use

Launch Date

Approved Use

Launch Date

Cmax

AUC

T1/2

Funbound

Doses

AEs

Overview

OverviewOther

Drug as perpetrator​

Sourcing

PubMed

Patents

Sample Use Guides

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021146s015lbl.pdf
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/mesh/68001285 | http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206289s000lbl.pdf

C_max

T_1/2

F_unbound

Drug as perpetrator